PT  - JOURNAL ARTICLE
AU  - Watson, Kelly M
AU  - Dasiewicz, Alison SB
AU  - Bassani, Diego G
AU  - Chen, Chun-Yuan
AU  - Qamar, Huma
AU  - O’Callaghan, Karen M
AU  - Roth, Daniel E
TI  - Height-age as an alternative to height-for-age z-scores to assess the effect of interventions on child linear growth in low- and middle-income countries
AID  - 10.1101/2024.07.15.24310427
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.15.24310427
4099  - http://medrxiv.org/content/early/2024/07/15/2024.07.15.24310427.short
4100  - http://medrxiv.org/content/early/2024/07/15/2024.07.15.24310427.full
AB  - Background Assessments of the efficacy of interventions to improve child growth are often based on differences in mean height-for-age z-scores (HAZ) and stunting (HAZ<-2) in randomized controlled trials (RCTs). However, this approach does not account for children’s starting skeletal age and does not enable assessment of the extent to which interventions optimized linear growth.Objective To develop and apply a new method using height-age to express linear growth effects in RCTs.Methods Longitudinal individual participant data (IPD) from a Bangladeshi trial cohort were used to compare height-age estimates derived from individual-level heights, mean raw height, or mean HAZ. Then, using average height-age as a proxy for skeletal age, we developed the ‘proportion of maximal benefit’ (PMB) metric to quantify intervention effects relative to optimal growth for children’s starting skeletal age. Optimal growth occurs when height-age increases in parallel with chronological age (i.e., PMB=100%) whereas no effect (versus control) corresponds to a PMB of 0%. Linear growth outcomes in 4 published RCTs of nutrition-specific interventions were re-expressed as mean height-age and PMB, and compared to effects conventionally expressed as intervention-versus-control mean differences (MD) in HAZ.Results Mean height-age could be derived from any published estimate of mean raw height or mean HAZ; however, to calculate the PMB, height or HAZ data were required at both the beginning and end of the observation period. Interpretations of intervention effects were consistent when expressed as either the height-age MD or HAZ MD. In contrast, the PMB does not have a corresponding metric on the HAZ scale, and therefore provided a new way to quantify intervention efficacy.Conclusion Height-age can be used as an alternative to HAZ to express intervention effects. The PMB has the advantage of conveying the extent to which an intervention improved average linear growth in relation to a biologically-defined benchmark.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKelly Watson was funded by the Canadian Institutes of Health Research (CIHR), through the Canadian Graduate Scholarship – Masters (CGS-M) and a project grant (#169133). The CIHR had no involvement in this study and does not restrict works for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research ethics board (REB) of The Hospital for Sick Children (SickKids) gave ethical approval for this work (SickKids REB #1000079659).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBONUSKidsBONe and mUScle health in KidsCIconfidence intervalDIVIDSDelhi Infant Vitamin D SupplementationHAZheight-for-age z-scoreIPDindividual participant dataLAZlength-for-age z-scoreLMICslow– and middle-income countriesLMSlambda-mu-sigmaMDmean differenceMDIGMaternal vitamin D for Infant GrowthPMBproportion of maximal benefitRCTrandomized controlled trialREBresearch ethics boardSDstandard deviationSEstandard errorSickKidsThe Hospital for Sick ChildrenWHO-GSWHO growth standards